Downstream Processing Featured Articles
-
FDA Approves New Seasonal Influenza Vaccine Made Using Novel Technology
1/16/2013
The U.S. Food and Drug Administration recently announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.
-
Theraclone Sciences Secures $14M In Additional Financing
3/25/2013
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, recently announced a $14M financing. $8M in equity is committed from existing investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo in a Series B Extension, bringing the total round to $50M.
-
Prospective Alzheimer’s Drug Builds New Brain Cell Connections
10/11/2012
Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer’s-like mental impairment.
-
NIH Scientists Map First Steps In Flu Antibody Development
8/29/2012
National Institutes of Health scientists have identified how a kind of immature immune cell responds to a part of influenza virus and have traced the path those cells take to generate antibodies that can neutralize a wide range of influenza virus strains. Study researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, were led by Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center. Their findings appear online in advance of print in Nature.
-
Scientists Show Protein-Making Machinery Can Switch Gears With A Small Structural Change
11/15/2012
For the past several years, Min Guo, an assistant professor at The Scripps Research Institute (TSRI), has focused on the intricate actions of an ancient family of catalytic enzymes that play a key role in translation, the process of producing proteins.
-
MMRGlobal Targets Phase 3 Biotech Companies To Combine Assets With Life Sciences Group
11/19/2012
MMRGlobal, Inc. (
OTCBB : MMRF) today announced that through its wholly owned subsidiary, MMR Life Sciences Group, the Company plans on exploiting its pipeline of biotech assets by facilitating a partnership or other joint venture with a privately held biotech company that has completed its Phase 2 clinical trials and is in the process of beginning Phase 3. -
CellCentric And ZoBio Enter Into Partnership To Develop Lead Compounds Against Epigenetic Drug Targets
6/20/2012
ZoBio and CellCentric are pleased to announce that the companies are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets. ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.
-
Announcing High Quality Borosilicate Glass Centrifuge Tubes
11/21/2011
Chemists are finding the optimal centrifuge tubes they need at Kimble Chase, the largest manufacturer of laboratory glassware products in the world.
-
Merck Assesses Single Use: Does It Make Sense At A Large Scale?
5/14/2014
In an industry as conservative as the pharmaceutical industry, it is common practice to be adverse to new technologies because they are often viewed as too much of a risk. However, in this effort to play it safe, companies force themselves into a repetitive state of employing technologies that may not be the most efficient or effective. Rather than getting stuck in old habits — or conversely, jumping too quickly into new ones — Merck has put together a group of teams it calls the Technology Encouragement Collaborators, or TEC, to look at new technologies and determine whether or not to implement them.
-
Successful Immunization And Safety Documented In Nasal Administration Study Of The HIV Vaccine Vacc-4x Together With Endocine
5/10/2012
Bionor Pharma ASA (
OSLO :BIONOR), Eurocine Vaccines AB and Oslo University Hospital today announced that vaccine related immune responses are documented in patients given active vaccine in a nasal immunization study, combining Bionor Pharma's Vacc-4x and Eurocine Vaccines' adjuvant Endocine.